AIM weekly movers: Ilika progresses development of Goliath battery

Ilika (LON: IKA) has reached the D6 milestone through the testing of 10Ah cells in its Goliath solid state batteries for electric vehicles. These larger cells have been shown to be safe and the D7 version should be available to potential customers in the second quarter of 2025. This moves the company nearer to finding a partner for the Goliath battery. The share price recovered 36.5% to 21.5p.

Guardian Metal Resources (LON: GMET) believes that the tightening of export controls by China enhances the potential for its tungsten project in Nevada. Drilling at the Pilot Mountain project is progressing well. This will support the pre-feasibility study, and the next batch of results should be available in the next few weeks. The share price increased 36.2% to 32p.

- Advertisement -

In the year to June 2024, Greatland Gold (LON: GGP) reported a net cash outflow from operating activities of £12.2m, which is slightly higher than the figure for the previous year. The capital spending fell from £28.8m to £13m. The acquisition of the remaining stake in Havieron gold copper project and readmission of the shares should happen in early December.  The share price rose 31.4% to 6.9p.

Programmatic advertising services provider Nexxen International (LON: NEXN) has launched a $50m share buyback ahead of asking shareholder permission at its AGM for a departure from AIM and change its Nasdaq listing from ADRs to ordinary shares. The share price improved 30.9% to 392p.

FALLERS

Webis (LON: WEB) has decided to leave AIM. The US-focused gaming company will seek shareholder approval on 18 December. This will help to reduce costs. The operations remain loss making. The share price slumped 79.2% to 0.125p.

- Advertisement -

Proton Motor Power Systems (LON: PPS) is going ahead with plans to leave AIM and winding down the business. Talks with a potential German industrial partner over funding have ended. The company has net liabilities. The share price dived 58.8% to 0.175p.

Cannabis-based medicines developer Celadon Pharmaceuticals (LON: CEL) has received a further £200,000 drawdown from the committed credit facility and the lender is committed to providing the remaining £500,000. However, it has to sell an investment to provide the cash. There is still £400,000 outstanding from a share subscription. Celadon Pharmaceuticals has enough cash to get it to January. Talks with another lender continue. The share price dipped 55.4% to 12.5p.

Caledonian Trust (LON: CNN) shareholders passed the resolution to leave AIM. The last day of trading is 25 November. The share price halved to 35p.

Latest News

Subscribe to the UK Investor Magazine email newsletter

Register for our free email newsletter and receive the latest investment news, podcasts, event information and offers.

More Articles Like This